Enzymlogic has validated the technical feasibility of KINETICfinder where GPCR was implemented. The robustness and sensitivity achieved are above the standard criteria in the pharma industry. The accuracy and reproducibility of data has been demonstrated and it is an environmentally friendly platform, reducing significantly the number of animals used in preclinical trials and avoiding the use of contaminating radioactive residues. In the business viability, Enzymlogic has validated the market niche of drug development analysis from an early stage worldwide, already having 3 customer of the top-10 global market. The area of biotechnological drugs also has a significant growth of 14.1%. Drugs are regarding cancer-targeted therapies and Alzheimer's disease as the most researched. The scalability analysis shows that due to the highly processability of the process. The revenue model based on a “Pay per Service” procedure has been validated, but some other revenues approaches will not be developed. A high-skilled commercial team will be required to keep the relationships with worldwide top-twenty Enzymlogic’s customers. In addition, the IPR strategy has been developed to protect further stages and once the technical, economic and commercial viability has been proven, Enzymlogic has already a complete business plan.